Publications by authors named "David Minor"

Claim this Profile
C
Carotid Artery Stenting.
Jun Li, Dmitriy N Feldman, Andrew J Klein, Mahmoud B Malas, D Christopher Metzger, David J Minor

J Soc Cardiovasc Angiogr Interv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas.
David R Minor, Kevin B Kim, R Krishna M Karuturi, Mohammed Kashani-Sabet

Front Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
David R Minor, Kevin B Kim, Ricky T Tong, Max C Wu, Mohammed Kashani-Sabet

Cancer Biother Radiopharm· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kevin B Kim, Liliana Soroceanu, David de Semir, Sherri Z Millis, Jeffrey Ross, David R Minor

J Invest Dermatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A Tarhini, Ni Kang, Sandra J Lee, F Stephen Hodi, Gary I Cohen, David R Minor

J Immunother Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sources of contamination in the operating room: A fluorescent particle powder study.
Holt S Cutler, Jose A Romero, David Minor, Michael H Huo

Am J Infect Control· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Ahmad A Tarhini, Sandra J Lee, F Stephen Hodi, Uma N M Rao, Gary I Cohen, David R Minor

J Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruit production is influenced by tree size and size-asymmetric crowding in a wet tropical forest.
David M Minor, Richard K Kobe

Ecol Evol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report of a Pregnancy During Ipilimumab Therapy.
Andrew Mehta, Kevin B Kim, David R Minor

J Glob Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
Elham Vosoughi, Jee Min Lee, James R Miller, Mehdi Nosrati, David R Minor

BMC Cancer· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin, David Minor, Sandra D'Angelo, Bart Neyns, Michael Smylie

J Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.
Jeff DeFalco, Michael Harbell, Amy Manning-Bog, Gilson Baia, Alexander Scholz, David Minor

Clin Immunol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer.
David R Minor, Samantha P Moores, John K Chan

Gynecol Oncol Rep· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F Stephen Hodi, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth F Grossmann, David R Minor

Lancet Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Igor Puzanov, Mohammed M Milhem, David Minor, Omid Hamid, Ai Li

J Clin Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
David R Minor, Igor Puzanov, Margaret K Callahan, Bruce A Hug, Axel Hoos

Pigment Cell Melanoma Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
John F Thompson, Sanjiv S Agarwala, B Mark Smithers, Merrick I Ross, Charles R Scoggins, David R Minor

Ann Surg Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, Anna C Pavlick, Caroline Robert, Kenneth Grossmann, David Minor

N Engl J Med· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer

Lancet Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Altaf A Dar, Mehdi Nosrati, Vladimir Bezrookove, David de Semir, Shahana Majid, David Minor

J Natl Cancer Inst· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Paolo A Ascierto, David Minor, Antoni Ribas, Celeste Lebbe, Anne O'Hagan

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
David R Minor, Stephen R Bunker, Judith Doyle

J Clin Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.
Heiner Ruschulte, Serena Shi, William W Tseng, Kerstin Kolodzie, Philip C Crawford, David Minor

BMC Anesthesiol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib.
David R Minor, Robert Rodvien, Mohammed Kashani-Sabet

Melanoma Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.
Niloofar Fadaki, Servando Cardona-Huerta, Lea Martineau, Suresh Thummala, Shih-Tsung Cheng, David Minor

BMJ Case Rep· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis